Análisis de la acción Damora Therapeutics Inc (DMRA)DMRADamora Therapeutics Inc

Damora Therapeutics, Inc. is a biotechnology company that focuses on hematologic disorders. It is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms (MPN), including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. Its lead asset, DMR-001, is an investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR). It is developing candidates for treatment of essential thrombocythemia (ET), an MPN associated with the overproduction of platelets, and myelofibrosis, an MPN involving the overproliferation of blood cells and deposition of fibrous material in the bone marrow and spleen. DMR-002, an afucosylated antibody designed to enhance antibody-dependent cellular cytotoxicity and amplify natural immune killing of malignant cells. DMR-003, a bi-specific T-cell engager antibody designed to recruit and direct T-cell-mediated killing of malignant cells. It operates in the Healthcare sector.

Damora Therapeutics (DMRA) is a good buy right now, trading at $21.09 with an RSI of 59.68, indicating bullish momentum. Analysts project a price target of $60, suggesting a potential upside of 184% from the current price. The recent 5-day price change of +14.37% shows positive short-term momentum, while the company has a solid cash position of $532.9 million to fund operations through 2029. However, the main risk is the negative earnings trend, with an EPS estimate of -0.52 for the next quarter, indicating ongoing losses.